http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Eun Sook Kim ),( Il Seong NamGoong ),( Gyung Yub Gong ),( Suck Joon Hong ),( Won Bae Kim ),( Young Kee Shong ) 대한내과학회 2003 The Korean Journal of Internal Medicine Vol.18 No.2
Background: Malignant follicular lesion is not differentiated from benign lesions cytologically. The objective of this study was to assess the rate and the risk of malignancy in thyroid nodules which were cytologically diagnosed as follicular neoplasm by
김하영,원종철,안일민,이태윤,이시열,류진숙,이성진,남궁일성,문대혁,한정희 대한내분비학회 2001 Endocrinology and metabolism Vol.16 No.4
Background: In patients with differentiated thyroid cancer treated by surgery and radioactive iodine ablation, serum thyroglobulin (Tg) and ^131I whole body scan (WBS) are recognized as being the best cooperative indicators for detection of recurrence or metastasis. However, in some cases, ^131I WBS shows no specific lesions despite elevated serum Tg. Therefore, 18-Fluorine-fluorodeoxyglucose (FDG) positron emission tomography (PET) has emerged as a useful method for the detection of ^131I WBS negative thyroid cancers. The aims of the present study are to evaluate the clinical usefulness of this technique in detection and to compare the results with ^99mTc-MIBI scintigraphy (MIBI) in cases of final results being confirmed by histologic diagnosis and other imaging methods. Methods: We conducted a retrospective analysis amon ^131I WBS negative recurred papillary thyroid carcinoma patients (male: female ratio=9:22, median age=42 yr). FDG PET was performed in 28 patients and MIBI 28 patients, 25 of whom were common to both groups. All patients had histologically proven recurrence/metastasis and negative ^131I WBS results but persistently elevated serum Tg levels. In each case overall clinical evaluations were performed including histology, cytology, thyroglobulin level, other imaging methods, posttherapy ^131I WBS and subsequent clinical course, to allow comparison with the results of FDG PET. Results: In 19 cases of patients with negative ^131I WBS, proven recurrence/metastasis lesions were detected in FDG PET. Compared with MIBI, FDG PET was found to be superior in 8 cases (including 2 patients with distant metastases). No FDG-negative/MIBI-positive tumor was observed. One FDG PET negative and MIBI negative case was proven 3 months later to be metastatic cervical lymph nodes, Sensitivities were 94.7% in the FDG PET group and 52.6% in MIBI. Diagnostic accuracy of FDG PET was superior to that of MIBI (93% vs. 62%, respectively, p=0.003). Conclusion: Our results confirmed the clinical usefulness of FDG PET for detection of ^131I negative differentiated thyroid cancers and suggested the value of FDG PET as an initial diagnostic step, rather than MIBI, in these cases
갑상선 안구병증에서 Lanreotide 요법의 임상적 이용
원종철,이은주,김상욱,안일민,한정희,이성진,이호규,남궁일성,김정훈,이우제,손무곤 대한내분비학회 2001 Endocrinology and metabolism Vol.16 No.1
Background: Graves ophthalmopathy (GO) is an autoimmune process that affects the orbital tissues. Patients with GO are usually treated with high doses of corticosteroids, retrobulbar irradiation, or by surgical decompression, however, those have some adverse effect. Recently, a synthetic somatostatin analogue has been reported for the treatment of GO. This study was performed prospectively to evaluate the therapeutic effects of lanreotide, a potent long acting synthetic somatmtatin analogue, in patients that have GO. Methods: Eight patients with moderate to severe GO (M:F=l:7, age 39.0+11.8 years) were included. Patients who had been treated with other modalities than GO, or had a systemic illness such as diabetes were excluded. Eight patients were given lanreotide, 40mg IM every 2 weeks over a period of 8 weeks. Their therapeutic responses were evaluated using an orbital CT or MRI and by ophthalmologic examinations. Results: After 8 weeks of lanreotide treatment, 4 patients showed decreased scores in the NOSPECS classification (p=0.059) as well as 5 patients in their clinical activity scores(p=0.109). All of the 8 patients showed improvements according to clinical evaluation criteria (p=0.008). Significant changes in the thics of both the lateral rectus and superior rectus muscles were observed (p$lt;0.05). No patient showed serious adverse effects related to lanreotide therapy during the follow-up periocL. Conclusion: We conclude that lanreotide therapy has clinical benefits and show radiologic improvements in GO. Considering the minimal side-effects of lanreotide compared to those of corticosteroid, lanreotide therapy should be considered tor use In selected patients that have Graves' ophthalmopathy (J Kor Soc Endocrinol 16:18-25, 200l)
Visfatin Stimulates Proliferation of MCF-7 Human Breast Cancer Cells
김재근,Eun Ok Kim,Bo Ra Jeong,Young Joo Min,박정우,Eun Sook Kim,Il Seong Namgoong,Young Il Kim,Byung Ju Lee 한국분자세포생물학회 2010 Molecules and cells Vol.30 No.4
Obesity, a condition characterized by increased fat content and altered secretion of adipokines, is a risk factor for postmenopausal breast cancer. Visfatin has recently been established as a novel adipokine that is highly enriched in visceral fat. Here we report that visfatin regulated prolifera-tion of MCF-7 human breast cancer cells. Exogenous ad-ministration of recombinant visfatin increased cell prolif-eration and DNA synthesis rate in MCF-7 cells. Further-more, visfatin activated G1-S phase cell cycle progression by upregulation of cyclin D1 and cdk2 expression. Visfatin also increased the expression of matrix metallopro-teinases 2, matrix metalloproteinases 9, and vascular en-dothelial growth factor genes, suggesting that it may func-tion in metastasis and angiogenesis of breast cancer. Taken together, these findings suggest that visfatin plays an important role in breast cancer progression.
Visfatin Stimulates Proliferation of MCF-7 Human Breast Cancer Cells
Kim, Jae-Geun,Kim, Eun-Ok,Jeong, Bo-Ra,Min, Young-Joo,Park, Jeong-Woo,Kim, Eun-Sook,NamGoong, Il-Seong,Kim, Young-Il,Lee, Byung-Ju Korean Society for Molecular and Cellular Biology 2010 Molecules and cells Vol.30 No.4
Obesity, a condition characterized by increased fat content and altered secretion of adipokines, is a risk factor for postmenopausal breast cancer. Visfatin has recently been established as a novel adipokine that is highly enriched in visceral fat. Here we report that visfatin regulated proliferation of MCF-7 human breast cancer cells. Exogenous administration of recombinant visfatin increased cell proliferation and DNA synthesis rate in MCF-7 cells. Furthermore, visfatin activated G1-S phase cell cycle progression by upregulation of cyclin D1 and cdk2 expression. Visfatin also increased the expression of matrix metalloproteinases 2, matrix metalloproteinases 9, and vascular endothelial growth factor genes, suggesting that it may function in metastasis and angiogenesis of breast cancer. Taken together, these findings suggest that visfatin plays an important role in breast cancer progression.
Kim, Jae Geun,Park, Byong Seo,Yun, Chang Ho,Kim, Hyun Jun,Kang, Sang Soo,D’Elia, Angela Valentina,Damante, Giuseppe,Lee, Ki-Up,Park, Jeong Woo,Kim, Eun Sook,Namgoong, Il Seong,Kim, Young Il,Lee, Byung American Diabetes Association 2011 Diabetes Vol.60 No.3
<P><B>OBJECTIVE</B></P><P>α-Melanocyte–stimulating hormone (α-MSH) and agouti-related peptide (AgRP) control energy homeostasis by their opposing actions on melanocortin receptors (MC3/4R) in the hypothalamus. We previously reported that thyroid transcription factor-1 (TTF-1) controls feeding behavior in the hypothalamus. This study aims to identify the function of TTF-1 in the transcriptional regulation of AgRP and α-MSH synthesis for the control of feeding behavior.</P><P><B>RESEARCH DESIGN AND METHODS</B></P><P>TTF-1 activity in AgRP and pro-opiomelanocortin (POMC) transcription was examined using gel-shift and promoter assays and an in vivo model of TTF-1 synthesis inhibition by intracerebroventricular injection of an antisense (AS) oligodeoxynucleotide (ODN). Double immunohistochemistry was performed to colocalize TTF-1 and AgRP or α-MSH in the hypothalamic arcuate nucleus (ARC). To determine whether TTF-1 action on food intake is mediated through MC3/4R, we measured changes in food intake upon intracerebroventricular injection of MC3/4R antagonists (SHU9119 and AgRP) into rat brain preinjected with the AS ODN.</P><P><B>RESULTS</B></P><P>TTF-1 stimulated AgRP but inhibited POMC transcription by binding to the promoters of these genes. TTF-1 was widely distributed in the hypothalamus, but we identified some cells coexpressing TTF-1 and AgRP or α-MSH in the ARC. In addition, intracerebroventricular administration of leptin decreased TTF-1 expression in the hypothalamus, and AS ODN-induced inhibition of TTF-1 expression decreased food intake and AgRP expression but increased α-MSH expression. Anorexia induced by the AS ODN was attenuated by the administration of MC3/4R antagonists.</P><P><B>CONCLUSIONS</B></P><P>TTF-1 transcriptionally regulates synthesis of AgRP and α-MSH in the ARC and affects feeding behavior via the melanocortin pathway.</P>